drugset / Trial / NCT03758781
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study is to determine the safety of IRX-2 Regimen combined with Nivolumab in patients with recurrent metastatic solid tumors. Researchers believe that this combination will have a tolerable safety profile and will increase the response rate in comparison to Nivolumab alone.
Timeline
- Start
- 2019-02-13
- Primary completion
- 2021-02-21
- Completion
- 2021-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IRX-2 | Protein / enzyme biologic | 4 ml | Subcutaneous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |